000			01993 a2200505 4500
005			20250516131325.0
264		0	_c20130920
008			201309s 0 0 eng d
022			_a1557-9700
024	7		_a10.1176/appi.ps.201200147 _2doi
040			_aNLM _beng _cNLM
100	1		_aKornfield, Rachel
245	0	0	_aEffects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008. _h[electronic resource]
260			_bPsychiatric services (Washington, D.C.) _cApr 2013
300			_a339-46 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAdolescent
650	0	4	_aAdrenergic Uptake Inhibitors _xtherapeutic use
650	0	4	_aAdrenergic alpha-2 Receptor Agonists _xtherapeutic use
650	0	4	_aAmphetamines _xtherapeutic use
650	0	4	_aAtomoxetine Hydrochloride
650	0	4	_aAttention Deficit Disorder with Hyperactivity _xdrug therapy
650	0	4	_aBupropion _xtherapeutic use
650	0	4	_aCentral Nervous System Stimulants _xtherapeutic use
650	0	4	_aChild
650	0	4	_aClonidine _xtherapeutic use
650	0	4	_aDopamine Uptake Inhibitors _xtherapeutic use
650	0	4	_aDrug Utilization
650	0	4	_aGuanfacine _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aPractice Patterns, Physicians' _xstatistics & numerical data
650	0	4	_aPropylamines _xtherapeutic use
650	0	4	_aUnited States
650	0	4	_aUnited States Food and Drug Administration
700	1		_aWatson, Sydeaka
700	1		_aHigashi, Ashley S
700	1		_aConti, Rena M
700	1		_aDusetzina, Stacie B
700	1		_aGarfield, Craig F
700	1		_aDorsey, E Ray
700	1		_aHuskamp, Haiden A
700	1		_aAlexander, G Caleb
773	0		_tPsychiatric services (Washington, D.C.) _gvol. 64 _gno. 4 _gp. 339-46
856	4	0	_uhttps://doi.org/10.1176/appi.ps.201200147 _zAvailable from publisher's website
999			_c22418849 _d22418849